BR112014019254A8 - Compostos moduladores de aurora e flt3 quinases e composições contendo os mesmos - Google Patents
Compostos moduladores de aurora e flt3 quinases e composições contendo os mesmosInfo
- Publication number
- BR112014019254A8 BR112014019254A8 BR112014019254A BR112014019254A BR112014019254A8 BR 112014019254 A8 BR112014019254 A8 BR 112014019254A8 BR 112014019254 A BR112014019254 A BR 112014019254A BR 112014019254 A BR112014019254 A BR 112014019254A BR 112014019254 A8 BR112014019254 A8 BR 112014019254A8
- Authority
- BR
- Brazil
- Prior art keywords
- aurora
- compositions containing
- flt3 kinase
- modulating compounds
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 title abstract 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 102000003989 Aurora kinases Human genes 0.000 abstract 1
- 108090000433 Aurora kinases Proteins 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPOSTOS MODULADORES DE AURORA E FLT3 QUINASES E COMPOSIÇÕES CONTENDO OS MESMOS. A invenção fornece um composto tendo a fórmula (1), útil como modulador da atividade da Aurora quinases, FLT3 quinases e sais dos mesmos, em que: R1 é hidrogênio ou C1-2 alquil; e R2, R3 e R4 são iguais ou diferentes, e cada um é selecionado dentre hidrogênio, C1-2 alquil, flúor, cloro, C1-2 alcóxi e trifluormetil, desde que não mais que dois dos R2, R3 e R4 sejam diferentes de hidrogênio. Também são fornecidas composições farmacêuticas contendo os compostos e seu uso na medicina e em particular no tratamento de câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1202027.7 | 2012-02-06 | ||
GBGB1202027.7A GB201202027D0 (en) | 2012-02-06 | 2012-02-06 | Pharmaceutical compounds |
PCT/EP2013/052182 WO2013117522A1 (en) | 2012-02-06 | 2013-02-04 | Aurora and flt3 kinases modulators |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014019254A2 BR112014019254A2 (pt) | 2017-06-20 |
BR112014019254A8 true BR112014019254A8 (pt) | 2017-07-11 |
BR112014019254B1 BR112014019254B1 (pt) | 2020-03-10 |
Family
ID=45896692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014019254-5A BR112014019254B1 (pt) | 2012-02-06 | 2013-02-04 | Compostos moduladores de aurora e flt3 quinases e composições contendo os mesmos |
Country Status (19)
Country | Link |
---|---|
US (1) | US9133180B2 (pt) |
EP (1) | EP2812328B1 (pt) |
JP (1) | JP6034880B2 (pt) |
KR (1) | KR102052780B1 (pt) |
CN (1) | CN104169277B (pt) |
AU (1) | AU2013218167B2 (pt) |
BR (1) | BR112014019254B1 (pt) |
CA (1) | CA2863759C (pt) |
DK (1) | DK2812328T3 (pt) |
ES (1) | ES2560260T3 (pt) |
GB (1) | GB201202027D0 (pt) |
HK (1) | HK1204327A1 (pt) |
IL (1) | IL233988A (pt) |
MX (1) | MX338481B (pt) |
PL (1) | PL2812328T3 (pt) |
PT (1) | PT2812328E (pt) |
RU (1) | RU2643809C2 (pt) |
SG (1) | SG11201404277WA (pt) |
WO (1) | WO2013117522A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105903847B (zh) * | 2016-06-03 | 2018-07-27 | 苏州赛腾精密电子股份有限公司 | 一种o型密封圈成形机构 |
MX2020001531A (es) * | 2017-08-07 | 2020-03-20 | Biocad Joint Stock Co | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
JPH06310767A (ja) | 1993-04-26 | 1994-11-04 | Nec Corp | 寒剤容器の断熱支持構造 |
EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
EE200200715A (et) | 2000-06-28 | 2004-08-16 | Astrazeneca Ab | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena |
CA2422617C (en) | 2000-10-30 | 2011-07-12 | Janssen Pharmaceutica N.V. | Tripeptidyl peptidase inhibitors |
CA2491895C (en) | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
AU2003902208A0 (en) * | 2003-05-08 | 2003-05-22 | Fujisawa Pharmaceutical Co., Ltd. | Inhibitor of cox |
PL1684750T3 (pl) | 2003-10-23 | 2010-10-29 | Ab Science | 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej |
US7572784B2 (en) * | 2004-05-14 | 2009-08-11 | Millennium Pharmaceuticals, Inc. | Compounds and methods for inhibiting mitotic progression |
GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
EP1932833B1 (en) | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
DK200600313A (da) | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
DE602007009085D1 (de) | 2006-05-12 | 2010-10-21 | Ab Science | Neues verfahren zur synthese von 2-aminooxazolverbindungen |
US20090093452A1 (en) * | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
WO2010011375A2 (en) | 2008-04-21 | 2010-01-28 | Merck & Co., Inc. | Inhibitors of janus kinases |
GB0820819D0 (en) * | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
EP2320293A1 (en) * | 2009-11-05 | 2011-05-11 | Koninklijke Philips Electronics N.V. | Sleep element for improving the sleep of a person |
CN102812022B (zh) * | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
PL2634185T3 (pl) | 2012-03-02 | 2016-06-30 | Sareum Ltd | Inhibitory kinazy TYK2 |
-
2012
- 2012-02-06 GB GBGB1202027.7A patent/GB201202027D0/en not_active Ceased
-
2013
- 2013-02-04 CN CN201380013544.5A patent/CN104169277B/zh active Active
- 2013-02-04 MX MX2014009323A patent/MX338481B/es active IP Right Grant
- 2013-02-04 SG SG11201404277WA patent/SG11201404277WA/en unknown
- 2013-02-04 DK DK13702642.3T patent/DK2812328T3/en active
- 2013-02-04 CA CA2863759A patent/CA2863759C/en active Active
- 2013-02-04 KR KR1020147024086A patent/KR102052780B1/ko active IP Right Grant
- 2013-02-04 RU RU2014131784A patent/RU2643809C2/ru active
- 2013-02-04 JP JP2014555250A patent/JP6034880B2/ja active Active
- 2013-02-04 EP EP13702642.3A patent/EP2812328B1/en active Active
- 2013-02-04 PL PL13702642T patent/PL2812328T3/pl unknown
- 2013-02-04 AU AU2013218167A patent/AU2013218167B2/en active Active
- 2013-02-04 US US14/376,729 patent/US9133180B2/en active Active
- 2013-02-04 BR BR112014019254-5A patent/BR112014019254B1/pt active IP Right Grant
- 2013-02-04 ES ES13702642.3T patent/ES2560260T3/es active Active
- 2013-02-04 PT PT137026423T patent/PT2812328E/pt unknown
- 2013-02-04 WO PCT/EP2013/052182 patent/WO2013117522A1/en active Application Filing
-
2014
- 2014-08-05 IL IL233988A patent/IL233988A/en active IP Right Grant
-
2015
- 2015-05-22 HK HK15104909.5A patent/HK1204327A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PT2812328E (pt) | 2016-03-01 |
HK1204327A1 (en) | 2015-11-13 |
ES2560260T3 (es) | 2016-02-18 |
US9133180B2 (en) | 2015-09-15 |
JP6034880B2 (ja) | 2016-11-30 |
MX338481B (es) | 2016-04-19 |
SG11201404277WA (en) | 2014-08-28 |
CA2863759A1 (en) | 2013-08-15 |
AU2013218167B2 (en) | 2017-04-06 |
US20150018367A1 (en) | 2015-01-15 |
EP2812328B1 (en) | 2015-11-18 |
CN104169277A (zh) | 2014-11-26 |
WO2013117522A1 (en) | 2013-08-15 |
RU2014131784A (ru) | 2016-03-27 |
DK2812328T3 (en) | 2016-01-11 |
PL2812328T3 (pl) | 2016-04-29 |
AU2013218167A1 (en) | 2014-08-14 |
CA2863759C (en) | 2020-04-14 |
BR112014019254B1 (pt) | 2020-03-10 |
CN104169277B (zh) | 2016-10-12 |
KR102052780B1 (ko) | 2019-12-05 |
RU2643809C2 (ru) | 2018-02-06 |
MX2014009323A (es) | 2015-04-08 |
IL233988A (en) | 2017-06-29 |
EP2812328A1 (en) | 2014-12-17 |
KR20140128373A (ko) | 2014-11-05 |
GB201202027D0 (en) | 2012-03-21 |
BR112014019254A2 (pt) | 2017-06-20 |
JP2015511228A (ja) | 2015-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
BR112015001613A8 (pt) | Compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica | |
TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
EA201591301A1 (ru) | Новые пиримидиновые и пиридиновые соединения и их применение | |
BR112015007083A2 (pt) | inibidores de histona demetilases | |
BR112017005531A2 (pt) | derivados de diaril ureia como inibidores de quinase p38 | |
NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
BR112015020242A2 (pt) | sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
BR112015027951A8 (pt) | arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit | |
EA201200952A1 (ru) | Производные пиразина и их применение для лечения неврологических нарушений | |
BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
BR112015005817A2 (pt) | compostos de bis(fluoroalquil)-1,4-benzodiazepinona como inibidores de notch | |
EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
BR112013032391A2 (pt) | antagonistas de trpv4 | |
BR112013001341A2 (pt) | compostos de pirimidina como inibidores de proteínas quinases ikk épsilon e/ou tbk-1, processo para a preparação dos mesmos e suas composições farmacêuticas | |
BR112017002214A2 (pt) | composto de fórmula (i), composição farmacêutica e usos de um composto | |
PH12014502056A1 (en) | 3,5-diaminopyrazole kinase inhibitors | |
BR112016006994A8 (pt) | inibidores de erk, seus usos e composições farmacêuticas os compreendendo | |
BR112015023356A2 (pt) | inibidores de quinase pirrol[2,3-b]piridina cdk9 | |
BR112015017331A2 (pt) | compostos químicos | |
EA200901389A1 (ru) | Производные фталазина и изохинолина с модулирующим действием на s1p рецепторы | |
EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
MA41337A (fr) | Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2013, OBSERVADAS AS CONDICOES LEGAIS. |